✦ LIBER ✦

Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia

✍ Scribed by Hisashi Sakamaki; Ken-ichi Ishizawa; Masafumi Taniwaki; Shin Fujisawa; Yasuo Morishima; Kensei Tobinai; Masaya Okada; Kiyoshi Ando; Noriko Usui; Shuichi Miyawaki; Atae Utsunomiya; Nobuhiko Uoshima; Tadashi Nagai; Tomoki Naoe; Toshiko Motoji; Itsuro Jinnai; Mitsune Tanimoto; Yasushi Miyazaki; Kazunori Ohnishi; Shinsuke Iida; Shinichiro Okamoto; Taku Seriu; Ryuzo Ohno

Book ID: 107618711
Publisher: Carden Jennings Publishing
Year: 2009
Tongue: English
Weight: 195 KB
Volume: 89
Category: Article
ISSN: 0925-5710
DOI: 10.1007/s12185-009-0260-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Lack of non-hematological cross intolera

Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis

✍ Yukio Kobayashi; Hisashi Sakamaki; Shin Fujisawa; Kiyoshi Ando; Kazuhito Yamamot 📂 Article 📅 2011 🏛 Carden Jennings Publishing 🌐 English ⚖ 152 KB

Expanding Nilotinib Access in Clinical T

Expanding Nilotinib Access in Clinical Trials (ENACT) : An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase

✍ Franck E. Nicolini; Anna Turkina; Zhi-Xiang Shen; Neil Gallagher; Saengsuree Joo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB 👁 2 views

## Abstract ## BACKGROUND: Nilotinib is a selective, potent BCR‐ABL inhibitor. Previous studies demonstrated the efficacy and safety of nilotinib in Philadelphia chromosome‐positive chronic myeloid leukemia patients in chronic phase (CML‐CP) or accelerated phase who failed prior imatinib. ## METH

High-dose imatinib mesylate combined wit

High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia

✍ Rea, D; Legros, L; Raffoux, E; Thomas, X; Turlure, P; Maury, S; Dupriez, B; Pign 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 100 KB

Prior treatment with the tyrosine kinase

Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia

✍ Shimoni, A; Leiba, M; Schleuning, M; Martineau, G; Renaud, M; Koren-Michowitz, M 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 103 KB

Location of breakpoints within the major

Location of breakpoints within the major breakpoint cluster region (bcr) in 33 patients with bcr rearrangement-positive chronic myeloid leukemia (CML) with complex or absent Philadelphia chromosomes

✍ Dr. Ian Dubé; Julie Dixon; Teresa Beckett; Abraham Grossman; Martha Weinstein; P 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 460 KB

We report the sublocalization of the breakpoint in chromosome 22 in 33 patients with chronic myeloid leukemia (CML) who also had unusual marrow cytogenetics. In 23 patients, the leukemic clones were characterized by Philadelphia (Ph') chromosomes that arose through complex translocations that involv

A Phase 2 study of combination therapy w

A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia

✍ Mikkael A. Sekeres; Jaroslaw P. Maciejewski; Harry P. Erba; Manuel Afable; Ricki 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB 👁 2 views